BioCryst Pharmaceuticals, Inc. (BCRX) Misses Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $7.65 -1.67%
EPS Growth %: -43.8%
Financial Fact:
Total expenses: 17M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: -43.8%
Financial Fact:
Total expenses: 17M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q2 EPS of ($0.36), $0.11 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $3.7 million versus the consensus estimate of $8.04 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioCryst to Report Third Quarter 2026 Financial Results on November 4
- First Hawaiian (FHB) Misses Q3 EPS by 7c
- World Acceptance (WRLD) Tops Q2 EPS by 113c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
